Active — Not RecruitingNot Applicable

Consistency of Response With Rimegepant in Acute Treatment of Migraine

United Kingdom250 participantsStarted 2025-11-15

Plain-language summary

This is a non-interventional, prospective study that will enroll participants with migraine in the United Kingdom currently in use of rimegepant to acutely treat migraine attacks. Participants will be followed up for up to 12 weeks and will complete a daily questionnaire to self-report the consistency of response to rimegepant in acute treatment of migraine.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. UK resident.
✓. At least 18 years of age.
✓. Migraine diagnosis confirmed by healthcare professional.
✓. Current prescription of rimegepant for acute treatment of migraine.
✓. Experienced at least 4 migraine attacks per month prior to study enrolment.
✓. In the case of participants receiving preventive migraine treatment:
✓. Evidence of a personally signed (or acknowledged if obtained electronically or online) and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study.

Exclusion criteria

✕. Current use of rimegepant as a preventive migraine medication.
✕. Current diagnosis of any of the following conditions:
✕. Current prescription of any of the following medications:
✕. Patients participating in a migraine-related clinical trial.

What they're measuring

Time to Meaninful Pain Relief (MPR) post-dosing

Timeframe: Daily (within 24hs post dose)

Trial details

NCT IDNCT06898047

SponsorPfizer

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-07-31

View on ClinicalTrials.gov More Migraine trials